Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer Pharmaceutical Investing
The Impact of Inaction - New Publication Reveals Not All of Canada is on Track to Meet Global Hepatitis C Elimination Goal Pharmaceutical Investing
AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Moderate to Severe Active Crohn's Disease Pharmaceutical Investing
AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting Pharmaceutical Investing
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial Life Science Investing
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma Life Science Investing
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases Pharmaceutical Investing
